New drug cocktail aims to shrink Hard-to-Treat carcinoid tumors
NCT ID NCT03950609
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase II trial tests whether combining lenvatinib and everolimus can shrink or slow advanced carcinoid tumors that cannot be removed by surgery. The study enrolls 36 adults with confirmed unresectable carcinoid tumors. Both drugs are taken orally and work by blocking enzymes that help cancer cells grow.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- lenvatinib and everolimus
- What this could lead to
- If successful, this combination could offer a new treatment option to shrink tumors and delay disease progression in people with advanced carcinoid tumors that cannot be surgically removed.
- What could go wrong
- This is a small, early-phase (Phase II) study with only 36 participants, so results may not apply to everyone. The drugs can cause side effects, and the trial is not designed to prove a cure or long-term benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CARCINOID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Double-Action antibody takes on Hard-to-Treat neuroendocrine cancers
- Experimental drug targets Hard-to-Treat neuroendocrine cancers
- New PET tracer could spot cancers that standard scans overlook
- New blood test may spot hidden tumors in MEN1 patients
- Can Full-Body scans spot cancer early in High-Risk families?
- Cancer care at home: a game changer for patients?